OGN INVESTIGATION: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Firm

Company Overview - Organon & Co. is a global healthcare company primarily focused on improving women's health [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon, specifically regarding false or misleading statements made by the company and its executives [1] - The investigation is aimed at determining whether Organon failed to disclose material information to investors [1] Recent Developments - On May 1, 2025, Organon announced a significant dividend cut of approximately 90%, which led to a stock price decline of more than 28% [3]